1.Ministry of Health of Brazil. Diseases – meningitis, chapter 5. In: Epidemiologic Guidelines, 6th edn. Secretariat for Health Surveillance, Brasilia, 2005, pp. 541–569.
2.Ahlawat, S, et al. Meningococcal meningitis outbreak control strategies. Journal of Communicable Diseases 2000; 32: 264–274.
3.Sistema de Alerta e Resposta Apropriada (SARA). Meningites: normas de procedimento, 2a edição. Lisboa: Direcção-Geral da Saúde, 1999, pp. 25.
4.Word Health Organization (WHO). Control of meningococcal epidemic disease. WHO practical guidelines, 2nd edn. Geneva, 1998.
5.Bilukha, OO, Rosenstein, N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report. Recommendations and Reports; 2005; 54 (RR-7): 1–21.
6.Stephens, DS, Greenwood, B, Brandtzaeg, P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007; 369: 2196–2210.
7.Weiss, D, et al. Epidemiologic investigation and targeted vaccination initiative in response to an outbreak of meningococcal disease among illicit drug users in Brooklyn, New York. Clinical Infectious Diseases 2009; 48: 894–901.
8.WHO. Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines. Weekly Epidemiological Record 2002; 77: 331–339.
9.WHO. Meningococcal meningitis. Weekly Epidemiological Record 2003; 78: 294–306.
10.Purcell, B, et al. Effectiveness of antibiotics in preventing meningococcal disease after a case: systematic review. British Medical Journal 2004; 328: 1339.
11.Granoff, DM, Harrison, LH, Borrow, R. Meningococcal vaccines. In: Plotkin, SA, Orenstein, WA, Offit, PA, eds. Vaccines. China: Elsevier; 2008, pp. 399–434.
12.Jackson, LA, et al. Serogroup C meningococcal outbreaks in the United States. An emerging threat. Journal of the American Medical Association 1995; 273: 383–389.
13.Popovic, T, Ajello, G, Facklam, R.Laboratory methods for the diagnosis of meningitis caused by Neisseria meningitidis, Streptococcus pneumonia, and Haemophilus influenzae. Atlanta, GA: Centers for Disease Control, World Health Organization, 1998.
14.Alkmin, MGA et al. Production and immunochemical characterization of Neisseria meningitidis group B antiserum for the diagnosis of purulent meningitis. Brazilian Journal of Medical and Biological Research 1994; 27: 1627–1634.
15.Mothershead, EA, et al. Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of Neisseria meningitidis. Journal of Clinical Microbiology 2004; 42: 320–328.
16.Carvalho, MGS, et al. Evaluation and improvement of real-time PCR assays targeting lytA, ply, and psaA genes for detection of pneumococcal DNA. Journal of Clinical Microbiology 2007; 45: 2460–2466.
17.Corless, CE, et al. Simultaneous detection of Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae in suspected cases of meningitis and septicemia using real-time PCR. Journal of Clinical Microbiology 2001; 39: 1553–1558.
18.Wedege, E, et al. Serotyping and subtyping of Neisseria meningitidis isolates by co-agglutination, dot-blotting and ELISA. Journal of Medical Microbiology 1990; 31: 195–201.
19.de Lemos, AP, et al. Clonal distribution of invasive Neisseria meningitidis serogroup C strains circulating from 1976 to 2005 in greater Sao Paulo, Brazil. Journal of Clinical Microbiology 2007; 45: 1266–1273.
20.CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Supplement M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA, 2006.
21.CLSI. Performance standards for antimicrobial susceptibility testing. Supplement M100-S18. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
22.Vazquez, JA. Resistance testing of meningococci: the recommendations of the European Monitoring Group on Meningococci. FEMS Microbiology Reviews 2007; 31: 97–100.
23.Popovic, T, et al. Evaluation of pulsed-field gel electrophoresis in epidemiological investigations of meningococcal disease outbreaks caused by Neisseria meningitidis serogroup C. Journal of Clinical Microbiology 2001; 39: 75–85.
24.Tenover, FC, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. Journal of Clinical Microbiology 1995; 33: 2233–2239.
25.Hartstein, AI, et al. Typing of sequential bacterial isolates by pulsed-field gel electrophoresis. Diagnostic Microbiology and Infectious Disease 1995; 22: 309–314.
26.Maiden, MC, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proceedings of the National Academy of Sciences of USA 1998; 95: 3140–3145.
27.Baethgen, LF, et al. Epidemiology of meningococcal disease in southern Brazil from 1995 to 2003, and molecular characterization of Neisseria meningitidis using multilocus sequence typing. Tropical Medicine and International Health 2008; 13: 31–40.
28.Biselli, R, et al. Dramatic reduction of meningococcal meningitis among military recruits in Italy after introduction of specific vaccination. Vaccine 1993; 11: 578–581.
29.CDC. Control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report. Recommendations and Reports 1997; 46 (RR-5): 13–21.
30.Moore, KA, Osterholm, MT. Meningococcal disease and public health practice: a complicated road map. Journal of the American Medical Association 1998; 279: 472–473.
31.Kaninda, AV, et al. Effectiveness of incidence thresholds for detection and control of meningococcal meningitis epidemics in northern Togo. International Journal of Epidemiology 2000; 29: 933–940.
32.Rosenstein, N, et al. Efficacy of meningococcal vaccine and barriers to vaccination. Journal of the American Medical Association 1998; 279: 435–439.
33.De Wals, P, et al. Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec, Canada. Bulletin of the World Health Organization 1996; 74: 407–411.
34.Artenstein, MS, et al. Prevention of meningococcal disease by group C polysaccharide vaccine. New England Journal of Medicine 1970; 282: 417–420.
35.Poland, GA. Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines. Clinical Infectious Diseases 2010; 50 (Suppl. 2): S45–53.
36.Begg, N. Policies for public health management of meningococcal disease. Journal of Epidemiology and Community Health 1999; 53: 516.